MOTS-c Benefits: What the Evidence Supports

What Are the Benefits of MOTS-c?

MOTS-c Explore PeRxMOTS-cThe Mitochondrial PeptideView peptide is studied for insulin sensitivity, glucose control, body composition, exercise capacity, and markers of healthy aging. The qualifier belongs in the same breath: those findings come from mice, cell cultures, and blood samples measuring the peptide people already produce. No completed study has injected MOTS-c into a person and measured whether any of it follows. That does not make the science weak. It makes the claims premature, and the difference is worth understanding before you spend anything.

How to Read the Evidence Grades

Pages listing MOTS-c benefits rarely say where each one came from, which lets a mouse study and a human trial sit side by side looking equally solid. Every claim below carries a tier instead, ordered by how much weight a finding can bear. The jump from tier 2 to tier 1 is the one almost nothing about MOTS-c has made yet.

MOTS-c Benefits, Graded

Insulin sensitivity and glucose

This is the best-supported claim and the reason the peptide exists in the literature at all. In the 2015 discovery paper, Lee and colleagues showed MOTS-c inhibits the folate cycle and the purine synthesis tethered to it, which activates AMPK, the same energy sensor metformin works through. Mice on a high-fat diet given 0.5 mg/kg daily for eight weeks were protected from obesity and from the rise in insulin that goes with it, and calorie intake was identical between groups, so eating less does not explain it. Seven days of treatment raised the glucose infusion rate about 30% in clamp studies, and muscle from 12-month-old mice regained insulin sensitivity comparable to 3-month-old animals.

Lee C, Zeng J, Drew BG, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism. 2015;21(3):443-454. PMID 25738459. View study

The nearest human echo comes from CB4211, a modified analog developed by CohBar, a company co-founded by the senior author of that discovery paper. In the four-week Phase 1b stage, 20 adults with obesity and fatty liver received 25 mg daily under the skin (11 people) or placebo (9). Against placebo, ALT fell 21%, AST fell 28% and glucose fell 6%, each reported as statistically significant, with a trend toward lower body weight. Liver fat measured by imaging dropped in both groups by almost the same amount, which is a useful reminder of how much a placebo arm moves. Results came by press release in August 2021, were never published in a journal, and the company moved to liquidate after its merger was terminated in November 2023.

Exercise capacity and muscle

Two separate findings get merged into one claim here, and pulling them apart changes what the evidence says. In mice, Reynolds and colleagues gave MOTS-c by injection and measured performance: treated animals ran longer and further on a treadmill, and mice started on an intermittent late-life course at roughly 24 months improved in grip strength, stride length and a 60-second walking test. In humans, the same paper measured something different. Ten sedentary young men rode a stationary bike, and their own MOTS-c rose about twelve-fold in muscle and roughly 1.5 to 1.6-fold in circulation, returning toward baseline after four hours of rest. Nobody was injected with anything.

Reynolds JC, Lai RW, Woodhead JST, et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications. 2021;12(1):470. PMID 33473109. View study

That human half is genuinely interesting biology. It is also the opposite arrow from the one a buyer cares about: exercise produces MOTS-c, which is not the same as MOTS-c producing the benefits of exercise. A related mouse and cell study found MOTS-c lowered myostatin, a brake on muscle growth, which is a plausible mechanism for the performance results and still sits at tier 4. Endurance-specific context lives in our guide on peptides for endurance athletes Read nextPeptides for Triathletes and Ironman AthletesHow peptide therapy is used for the three things long-course endurance breaks down: mitochondrial capacity, overuse tendon injury, and recovery between sessions. With an honest read on what is legal under WADA and what is not.Read article , with the caveat that this peptide is banned in tested sport.

Kumagai H, Coelho AR, Wan J, et al. "MOTS-c reduces myostatin and muscle atrophy signaling." American Journal of Physiology. Endocrinology and Metabolism. 2021;320(4):E680-E690. PMID 33554779. View study

Bone, heart, and longevity

These are the thinnest of the commonly listed benefits. Bone rests on two rodent and cell studies: ovariectomized mice given 5 mg/kg daily for 12 weeks lost less bone on micro-CT, and a separate study found MOTS-c pushed rat marrow stem cells toward bone-forming cells in culture. A 2025 rat study reported improved cardiac mitochondrial respiration in diabetic hearts. On longevity, the late-life mouse experiment showed a trend toward longer median and maximum lifespan that did not reach significance, and the authors wrote that larger groups would be needed. The human longevity angle is a genetic hypothesis, not a finding: a 2015 paper suggested that a variant in the MOTS-c coding region specific to Northeast Asian populations might help explain Japanese longevity, and said more research was needed. A later study linked that same variant to higher type 2 diabetes prevalence in men. Genetics is not a treatment result.

Ming W, Lu G, Xin S, et al. "Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation." Biochemical and Biophysical Research Communications. 2016;476(4):412-419. PMID 27237975. View study

Hu BT, Chen WZ. "MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-β/Smad pathway." European Review for Medical and Pharmacological Sciences. 2018;22(21):7156-7163. PMID 30468456. View study

Pham T, Taberner A, Hickey A, et al. "Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart." Frontiers in Physiology. 2025;16:1602271. PMID 40661667. View study

Fuku N, Pareja-Galeano H, Zempo H, et al. "The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?" Aging Cell. 2015;14(6):921-923. PMID 26289118. View study

Zempo H, Kim SJ, Fuku N, et al. "A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c." Aging (Albany NY). 2021;13(2):1692-1717. PMID 33468709. View study

Your Own MOTS-c vs an Injection

Most human MOTS-c research measures the peptide in blood and correlates it with something. That work is real, and it is routinely quoted as though it were evidence for injecting. Two problems come with it. The first is direction: an association cannot tell you whether low MOTS-c drives a condition, results from it, or simply travels alongside it. The second is that the associations themselves do not line up neatly.

The third row is the one worth sitting with. If higher circulating MOTS-c were straightforwardly better, you would not expect it to track with worse insulin sensitivity in lean adults. The authors read it as the peptide responding to metabolic status rather than setting it, which is a different model of what MOTS-c is for.

Cataldo LR, Fernández-Verdejo R, Santos JL, Galgani JE. "Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals." Journal of Investigative Medicine. 2018;66(6):1019-1022. PMID 29593067. View study

Ramanjaneya M, Bettahi I, Jerobin J, et al. "Mitochondrial-Derived Peptides Are Down Regulated in Diabetes Subjects." Frontiers in Endocrinology. 2019;10:331. PMID 31214116. View study

Du C, Zhang C, Wu W, et al. "Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance." Pediatric Diabetes. 2018. PMID 29691953. View study

D'Souza RF, Woodhead JST, Hedges CP, et al. "Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition." Aging (Albany NY). 2020;12(6):5244-5258. PMID 32182209. View study

The Dose Gap Nobody Mentions

Even granting the mouse results, there is an arithmetic problem between those studies and what gets prescribed. Animal doses do not transfer to people directly, and the FDA’s own conversion guidance uses a body-surface-area factor of 12.3 for mice. Run the two headline studies through it and they land in very different places.

Two things follow. The metabolic findings were produced at a dose a person could plausibly receive, which is a point in their favor and rarely mentioned. The performance findings were not, so the treadmill result most often used to sell MOTS-c came from an exposure far above anything prescribed. Surface-area conversion is a rough starting-dose tool, not a precise translation, and nobody has run the pharmacokinetic study that would settle it. Dosing itself belongs to the MOTS-c dosage chart Read nextMOTS-c Dosage Chart: Units, Protocols & EffectsMOTS-c is the 16-amino-acid mitochondrial peptide your body releases during exercise. This guide leads with what most readers came for: a real dosage chart with per-injection amounts, insulin syringe unit conversions, weekly totals, and cycle lengths. Then it covers the AMPK mechanism, the metformin comparison, the 2015 USC discovery story, and an honest read of the evidence.Read article .

MOTS-c for Weight Loss

Searches for a MOTS-c weight-loss dose are common, so here is the direct answer: there is not one. No dose has been tested against weight in a human trial, which means any number presented as a weight-loss protocol was chosen by inference. The underlying evidence is the mouse work, where animals on a high-fat diet gained less weight at matched calorie intake, plus a trend toward lower body weight in the four-week analog study that did not reach the bar its other endpoints cleared.

FDA staff noted that obesity is a serious condition with approved treatments already available, and declined to evaluate obesity as a proposed use because the nomination lacked the information to support it. PeRx does not prescribe MOTS-c as a weight-loss treatment. If fat loss is the actual goal, our guides on whether peptides help you lose weight Read nextDo Peptides Help You Lose Weight? An Honest AnswerSome peptides genuinely help people lose weight. Most of the ones sold online do not. The line between the two is not marketing, it is drug class, and you can learn where it sits in about ten minutes. This page gives the verdict first and the reasoning after.Read article and the best peptides for fat loss Read nextBest Peptides for Fat Loss: Ranked by EvidenceMost rankings of fat-loss peptides are marketing dressed up as science. This one is built the way a prescribing clinic actually thinks: four tiers, ordered by the strength of the human evidence, with an honest section on the peptides that are not worth your money at all.Read article cover the options with real outcome data, including the GLP-1 medications. Anyone already on one should read MOTS-c and semaglutide Read nextMOTS-c and Semaglutide: Can You Combine Them?Ask this question online and you get two kinds of answers. Retail sites say yes and quote fat-loss percentages that do not exist anywhere in the literature. Cautious sites say nothing has been studied and stop there. Both halves are doing part of the job. This page does the whole thing: what is actually known, including the analog trial almost nobody mentions, and how a prescribing clinic thinks about the combination in practice.Read article before adding anything.

What People Report Noticing

Separate from the literature, there is what patients say. It belongs in its own category: uncontrolled, unblinded, and exactly the kind of thing a placebo produces reliably. The analog trial is the reminder, since liver fat improved nearly as much on placebo as on drug.

Realistic timelines across the catalog are covered in how long peptides take to work Read nextHow Long Do Peptides Take to Work?Anywhere from the same evening to several months, depending on which peptide and which change you are watching for. PT-141 is dosed for a same-day window while GHK-Cu skin remodeling is a months-long project, and most peptides land somewhere between. This guide maps the typically reported onset windows by peptide family, explains what tends to change first for each goal, and covers why feeling nothing early is often normal rather than a sign of failure.Read article , and the case where nothing happens is covered in what if a peptide does not work for you Read nextPeptide Not Working? Timelines, Causes and Next StepsMost peptide marketing implies a guaranteed outcome. The honest answer is that no peptide works for everyone, and the question worth asking before you start is what happens if it does not work for you. Here is what "not working" actually looks like, the realistic timelines so you do not quit too early, the real reasons a peptide underdelivers, and the next steps when one is not earning its place.Read article .

Who It Fits, and Who It Does Not

The full safety picture, including blood sugar and the cancer question, is in MOTS-c side effects Read nextMOTS-c Side Effects: What Is Known and What Is NotEvery MOTS-c side-effect list online shares one problem: no study of injected MOTS-c in people has ever reported results, so none of those lists has a number behind it. This page sorts the evidence into what was measured in humans (almost nothing, mostly on an analog), what FDA reviewers flagged in 2026, and what users report, with straight answers on blood sugar, cancer, and the heart.Read article . The intake review itself is covered in what providers review before prescribing Read nextWhat Providers Review Before Prescribing PeptidesWhen your intake reaches a licensed provider, it is not a rubber stamp. There is a specific list they run down before any peptide is approved: the conditions that change whether a peptide is safe, the medication classes that have to be cross-checked, and the reasons an order gets sent back or declined. Here is that list, from the provider’s side of the screen.Read article .

MOTS-c

PeRx MOTS-c is prescribed by a licensed provider after a health and medication review, compounded by a US-based 503A pharmacy at a fixed 2 mg/mL, and tested for potency and sterility. It arrives ready to use with no reconstitution needed, so the concentration on the label is the concentration in the vial.

That fixed concentration matters more here than for most peptides. FDA reviewers observed that certificates of analysis circulating for MOTS-c typically report a purity number and nothing about aggregates or impurities, and a peptide of unverified identity is a poor starting point for judging whether anything worked. $229 for a one-month supply, with syringes and swabs included.

Compounded at a fixed 2 mg/mL and dispensed only after provider review.

Shop Now

What the Phase 2a Trial Will Answer

A randomized, double-blind, placebo-controlled Phase 2a study called MOTS-MET (NCT07505745) began recruiting on February 2, 2026. It plans about 120 adults aged 18 to 65 with prediabetes and a BMI between 27 and 40, randomized one to one to a fixed daily subcutaneous dose or placebo for 12 weeks, with both arms receiving lifestyle counseling. The primary measures are insulin sensitivity by the Matsuda index at 12 weeks and treatment-emergent adverse events through week 16. HbA1c, fasting glucose, two-hour glucose and anti-drug antibodies are secondary. Primary completion is estimated for February 14, 2027.

One process note, because it gets conflated with evidence. On July 23, 2026 the Pharmacy Compounding Advisory Committee voted 7 to 5, with two abstentions, to recommend MOTS-c for the 503A bulks list, against the FDA staff position. That vote is advisory, nothing has been finalized as of September 2026, and the regulatory status remains unsettled. A committee recommending that pharmacies be allowed to compound something is not a finding that it works. The FDA panel vote Read nextFDA Panel Backs 6 of 7 Peptides, Rejects DSIPThe FDA's Pharmacy Compounding Advisory Committee finished its two-day meeting on July 24, 2026. By the end, it had voted to recommend six of the seven peptides on the agenda for the 503A compounding list, including BPC-157, TB-500, MOTS-C, Semax, and Epitalon, and against just one, Emideltide (DSIP). Every vote went against the FDA's own scientists. Here is the full tally, what it changes, and what it does not.Read article and MOTS-c FDA status Read nextIs MOTS-c FDA Approved? Mitochondrial Peptide StatusNo. MOTS-C was only discovered in 2015. It is the newest peptide in clinical use and the first peptide ever found to be encoded by mitochondrial DNA rather than nuclear DNA. That discovery, from Changhan David Lee's lab at USC, upended decades of assumptions about where bioactive peptides come from. Here is what we know so far.Read article pages have the detail.

MOTS-c Benefits: Common Questions